Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population

BACKGROUND: Hyperglycemia and new-onset diabetes mellitus have been reported to occur in HIV-infected patients treated with protease inhibitors. OBJECTIVE: To determine the effect of protease inhibitor therapy on serum glucose in a predominantly minority patient population. DESIGN: Retrospective rec...

Full description

Saved in:

Bibliographic Details
Published in:	The Annals of pharmacotherapy Vol. 34; no. 5; pp. 580 - 584
Main Authors:	Dever, LL, Oruwari, PA, Figueroa, WE, O'Donovan, CA, Eng, RH
Format:	Journal Article
Language:	English
Published:	Cincinnati, OH Harvey Whitney Books 01-05-2000 SAGE Publications Whitney
Subjects:	Adult Biological and medical sciences Blood Glucose - analysis Diabetes Mellitus, Type 2 - chemically induced Drug toxicity and drugs side effects treatment Female HIV Infections - drug therapy HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - therapeutic use Humans Hyperglycemia - chemically induced Indinavir - adverse effects Indinavir - therapeutic use Male Medical sciences Middle Aged Minority Groups - statistics & numerical data Miscellaneous (drug allergy, mutagens, teratogens...) Pharmacology. Drug treatments Retrospective Studies Risk Factors Ritonavir - adverse effects Ritonavir - therapeutic use Saquinavir - adverse effects Saquinavir - therapeutic use Urban Population - statistics & numerical data protease inhibitors hyperglycemia HIV infection Endocrinopathy Human Immunopathology Toxicity Diabetes mellitus Retroviridae AIDS Immune deficiency Lentivirus Infection Virus Chemotherapy Hyperglycemia Treatment Viral disease Antiviral Human immunodeficiency virus Protease inhibitor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	BACKGROUND: Hyperglycemia and new-onset diabetes mellitus have been reported to occur in HIV-infected patients treated with protease inhibitors. OBJECTIVE: To determine the effect of protease inhibitor therapy on serum glucose in a predominantly minority patient population. DESIGN: Retrospective record review. SETTING: Clinical HIV program of an urban Veterans Affairs medical center. PATIENTS: All HIV-infected patients receiving a protease inhibitor over a one-year period from September 1996 through August 1997. RESULTS: One hundred seventeen patients not previously known to be diabetic received protease inhibitors; seven (6%) developed symptomatic diabetes mellitus. Eight other patients had one or more serum glucose values >150 mg/dL. Mean random glucose values for patients who did not develop diabetes were higher during therapy than prior to initiation of protease inhibitors. CONCLUSIONS: Urban minority HIV-infected patients receiving combination antiretroviral therapy including a protease inhibitor may be at increased risk for the development of hyperglycemia and diabetes mellitus. Risk factors for diabetes mellitus should be identified and blood glucose monitored in all patients receiving protease inhibitors.
ISSN:	1060-0280 1542-6270
DOI:	10.1345/aph.19231